Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tiziana Life Sciences ( (TLSA) ) has provided an update.
On December 2, 2025, Tiziana Life Sciences announced its intention to spin out its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, into a separate publicly traded company. This strategic move aims to enhance the focus of each company and drive shareholder value, with Tiziana shareholders retaining value through distribution in specie of shares in the new entity. The decision is influenced by increased industry interest in IL-6 pathway therapeutics, highlighted by Novartis’ recent acquisition of Tourmaline Bio. The spinout will allow Tiziana to concentrate on its lead program, intranasal foralumab, while dedicating resources to the development of TZLS-501.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulation therapies. The company employs transformational drug delivery technologies, particularly emphasizing intranasal delivery methods. Tiziana’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, aiming to treat neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 332,269
Technical Sentiment Signal: Buy
Current Market Cap: $199.5M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.